229 related articles for article (PubMed ID: 16026362)
1. Pioglitazone initiation and subsequent hospitalization for congestive heart failure.
Karter AJ; Ahmed AT; Liu J; Moffet HH; Parker MM
Diabet Med; 2005 Aug; 22(8):986-93. PubMed ID: 16026362
[TBL] [Abstract][Full Text] [Related]
2. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis.
Rajagopalan R; Rosenson RS; Fernandes AW; Khan M; Murray FT
Clin Ther; 2004 Sep; 26(9):1400-10. PubMed ID: 15531002
[TBL] [Abstract][Full Text] [Related]
3. Thiazolidinediones and congestive heart failure in veterans with type 2 diabetes.
Toprani A; Fonseca V
Diabetes Obes Metab; 2011 Mar; 13(3):276-80. PubMed ID: 21205120
[TBL] [Abstract][Full Text] [Related]
4. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
Wang CC; Chen WL; Kao TW; Chang YW; Loh CH; Chou CC
Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894
[TBL] [Abstract][Full Text] [Related]
5. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.
Lu CJ; Sun Y; Muo CH; Chen RC; Chen PC; Hsu CY
Cerebrovasc Dis; 2013; 36(2):145-51. PubMed ID: 24029780
[TBL] [Abstract][Full Text] [Related]
6. Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database.
Fadini GP; Avogaro A; Degli Esposti L; Russo P; Saragoni S; Buda S; Rosano G; Pecorelli S; Pani L;
Eur Heart J; 2015 Sep; 36(36):2454-62. PubMed ID: 26112890
[TBL] [Abstract][Full Text] [Related]
7. Development of heart failure in Medicaid patients with type 2 diabetes treated with pioglitazone, rosiglitazone, or metformin.
Breunig IM; Shaya FT; McPherson ML; Snitker S
J Manag Care Spec Pharm; 2014 Sep; 20(9):895-903. PubMed ID: 25166288
[TBL] [Abstract][Full Text] [Related]
8. The incidence of congestive heart failure associated with antidiabetic therapies.
Nichols GA; Koro CE; Gullion CM; Ephross SA; Brown JB
Diabetes Metab Res Rev; 2005; 21(1):51-7. PubMed ID: 15386819
[TBL] [Abstract][Full Text] [Related]
9. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
Ziyadeh N; McAfee AT; Koro C; Landon J; Arnold Chan K
Clin Ther; 2009 Nov; 31(11):2665-77. PubMed ID: 20110009
[TBL] [Abstract][Full Text] [Related]
10. Antidiabetic therapy and the risk of heart failure in type 2 diabetic patients: an independent effect or confounding by indication.
Koro CE; Bowlin SJ; Weiss SR
Pharmacoepidemiol Drug Saf; 2005 Oct; 14(10):697-703. PubMed ID: 15654719
[TBL] [Abstract][Full Text] [Related]
11. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.
Mamtani R; Haynes K; Bilker WB; Vaughn DJ; Strom BL; Glanz K; Lewis JD
J Natl Cancer Inst; 2012 Sep; 104(18):1411-21. PubMed ID: 22878886
[TBL] [Abstract][Full Text] [Related]
12. Thiazolidinedione use is not associated with worse cardiovascular outcomes: a study in 28,332 high risk patients with diabetes in routine clinical practice: brief title: thiazolidinedione use and mortality.
Roussel R; Hadjadj S; Pasquet B; Wilson PW; Smith SC; Goto S; Tubach F; Marre M; Porath A; Krempf M; Bhatt DL; Steg PG
Int J Cardiol; 2013 Aug; 167(4):1380-4. PubMed ID: 22560911
[TBL] [Abstract][Full Text] [Related]
13. [Glitazones and congestive heart failure: update on PROactive, ADOPT, DREAM and RECORD clinical trials].
De Flines J; Scheen AJ
Rev Med Suisse; 2007 Aug; 3(122):1876, 1878-83. PubMed ID: 17896661
[TBL] [Abstract][Full Text] [Related]
14. The association between adherence to oral anti-diabetic drugs and hypoglycaemia in persons with Type 2 diabetes.
Quilliam BJ; Ozbay AB; Sill BE; Kogut SJ
Diabet Med; 2013 Nov; 30(11):1305-13. PubMed ID: 23586474
[TBL] [Abstract][Full Text] [Related]
15. Thiazolidinedione-induced congestive heart failure.
Cheng AY; Fantus IG
Ann Pharmacother; 2004 May; 38(5):817-20. PubMed ID: 15039476
[TBL] [Abstract][Full Text] [Related]
16. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
Acta Diabetol; 2009 Jun; 46(2):145-54. PubMed ID: 19194648
[TBL] [Abstract][Full Text] [Related]
17. Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone.
Rajagopalan R; Iyer S; Perez A
Diabetes Obes Metab; 2005 Mar; 7(2):161-9. PubMed ID: 15715889
[TBL] [Abstract][Full Text] [Related]
18. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.
Tzoulaki I; Molokhia M; Curcin V; Little MP; Millett CJ; Ng A; Hughes RI; Khunti K; Wilkins MR; Majeed A; Elliott P
BMJ; 2009 Dec; 339():b4731. PubMed ID: 19959591
[TBL] [Abstract][Full Text] [Related]
19. A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes.
Gerrits CM; Bhattacharya M; Manthena S; Baran R; Perez A; Kupfer S
Pharmacoepidemiol Drug Saf; 2007 Oct; 16(10):1065-71. PubMed ID: 17674425
[TBL] [Abstract][Full Text] [Related]
20. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes.
Lipscombe LL; Gomes T; Lévesque LE; Hux JE; Juurlink DN; Alter DA
JAMA; 2007 Dec; 298(22):2634-43. PubMed ID: 18073359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
